- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00918853
Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas (MRP)
March 19, 2015 updated by: Institut Paoli-Calmettes
Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas.
This multicentric prospective study evaluates the role of the margins resection and the ganglionic status when using a quality standard for the resection of adenocarcinoma of the head of the pancreas.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Primary objective:
- Evaluation of the prognosis role of the invasion of the margins on the overall survival after a standard resection of adenocarcinoma of the head of the pancreas.
Secondary objectives:
Evaluation of the prognosis role of the invasion:
- Of margins on the overall survival.
- Of each margins (distal pancreatic margin, gastric, posterior, retro-venous, retro-arterial) on the overall survival.
- Of the ganglionic group of the superior mesenteric artery and the other nodes.
Study Type
Interventional
Enrollment (Actual)
156
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Angers, France
- CHU d'Angers
-
Bordeaux, France
- CHU de Bordeaux
-
Boulogne, France
- Hôpital Ambroise Paré
-
Clermont-ferrand, France
- CHU de Clermont-Ferrand
-
Clichy, France
- Hopital Beaujon
-
Creteil, France
- Hôpital Henri Mondor
-
Lyon, France
- Hospices Civils de LYON
-
Lyon, France
- Hôpital de la Croix-Rousse
-
Lyon, France
- Hopital de L'Antiquaille
-
Marseille, France
- Institut Paoli-Calmettes
-
Marseille, France
- CHU la Conception
-
Montpellier, France
- Centre Val d'Aurelle Paul Lamarque
-
Nantes, France
- Hotel Dieu
-
Paris, France
- Hôpital Pitié-Salpêtrière
-
Paris, France
- Hôpital Cochin
-
Paris, France
- Hopital Tenon
-
Paris, France
- Hopitial Saint Antoine
-
Rennes, France
- Hopital Pontchaillou
-
Strasbourg, France
- Hôpitaux Universitaires de Strasbourg
-
Toulouse, France
- CHU Purpan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- A head of the pancreas tumor compatible with adenocarcinoma diagnosis
- tumor apparently removable
- patient aged from 18 to older
- signed consent
Non inclusion criteria:
- pregnancy, breast feeding
- patient in an urgency situation or patient with legal protection
Exclusion Criteria after surgery:
- tumor other than adenocarcinoma of the head of the pancreas.
- analysis of the margins not done with the defined criteria
- nonadhesion to the surgical protocol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: resection for adenocarcinoma
quality standard resection for adenocarcinoma of the head of the pancreas
|
quality standard for the resection of adenocarcinoma of the head of the pancreas
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prognostic value of the invasion of the margins measured in millimetres on the overall survival
Time Frame: 4 years
|
4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Relapse free survival: time between surgery and relapse or a right censure. The relapse is determined by clinical examination, biologic examination and imaging, which reveals metastasis or an isolated local relapse
Time Frame: 4 years
|
4 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jean Robert DELPERO, PhD, Institut Paoli-Calmettes
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Delpero JR, Jeune F, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Adham M, Autret A, Poizat F, Turrini O, Boher JM. Prognostic Value of Resection Margin Involvement After Pancreaticoduodenectomy for Ductal Adenocarcinoma: Updates From a French Prospective Multicenter Study. Ann Surg. 2017 Nov;266(5):787-796. doi: 10.1097/SLA.0000000000002432.
- Delpero JR, Bachellier P, Regenet N, Le Treut YP, Paye F, Carrere N, Sauvanet A, Autret A, Turrini O, Monges-Ranchin G, Boher JM. Pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a French multicentre prospective evaluation of resection margins in 150 evaluable specimens. HPB (Oxford). 2014 Jan;16(1):20-33. doi: 10.1111/hpb.12061. Epub 2013 Mar 7.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2008
Primary Completion (Actual)
May 1, 2012
Study Completion (Actual)
May 1, 2012
Study Registration Dates
First Submitted
June 9, 2009
First Submitted That Met QC Criteria
June 10, 2009
First Posted (Estimate)
June 11, 2009
Study Record Updates
Last Update Posted (Estimate)
March 20, 2015
Last Update Submitted That Met QC Criteria
March 19, 2015
Last Verified
March 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRP/IPC 2007-005
- ID-RCB 2007-A01326-47
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adenocarcinoma
-
Criterium, Inc.University of Colorado, Denver; NovartisTerminatedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular AdenocarcinomaUnited States
-
University of ChicagoCompletedGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Weill Medical College of Cornell UniversityMerck Sharp & Dohme LLC; Oncolys BioPharma IncRecruitingGastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditionsUnited States, Puerto Rico
-
Roswell Park Cancer InstituteUnited States Department of DefenseRecruitingClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Locally Advanced Gastroesophageal Junction... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingPancreas Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
National Cancer Institute (NCI)Not yet recruitingClinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingGastroesophageal Junction Adenocarcinoma | Clinical Stage II Esophageal Adenocarcinoma AJCC v8 | Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage II Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage IIA Esophageal... and other conditionsUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
Clinical Trials on resection of adenocarcinoma of the head of the pancreas
-
Betta Pharmaceuticals Co., Ltd.Unknown
-
Lithuanian Sports UniversityCompletedMultiple SclerosisLithuania
-
Betta Pharmaceuticals Co., Ltd.UnknownLung Cancer | ROS1 Gene RearrangementChina
-
Nantes University HospitalRennes University HospitalNot yet recruiting
-
Wakayama Medical UniversityUnknown
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Boston Scientific CorporationCompletedBenign Prostatic HyperplasiaUnited Kingdom, Germany, Austria, Spain, Belgium, France, Italy, Netherlands, Switzerland
-
Vastra Gotaland RegionSahlgrenska University Hospital, Sweden; The Göteborg Medical Society, SwedenCompletedGastric Cancer | Cancer of EsophagusSweden
-
Fundacion Miguel ServetCompletedLower Urinary Tract Symptoms | Benign Prostatic Hyperplasia | Transurethral Resection of Prostate | Artery EmbolizationSpain
-
Mansoura UniversityCompletedSexual Functions and Problems in the AdultEgypt